ENDRA Life Sciences Inc（NDRA）财务数据NDRAENDRA Life Sciences Inc

Evaluating the bottom line, ENDRA Life Sciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -152.04%, provide a clear picture of how effectively NDRA converts its operational activities into shareholder value.

In the context of the broader market, NDRA competes directly with industry leaders such as BMRA and CLGN. With a market capitalization of $7.09M, it holds a significant position in the sector. When comparing efficiency, NDRA's gross margin of N/A stands against BMRA's 8.14% and CLGN's -422.22%. Such benchmarking helps identify whether ENDRA Life Sciences Inc is trading at a premium or discount relative to its financial performance.

Endra Life Sciences has struggled financially, with total revenue of only $211,600 in Q1 2025 and a net income loss of $1,311,433 in Q1 2026. The company has also shown a concerning trend with a negative gross profit in multiple quarters, indicating ongoing operational challenges.